ECCTA failure to prevent fraud for pharmaceuticals and life sciences
Pharmaceutical and life sciences companies run global trials, complex distribution chains, and prescriber and payer relationships — areas where fraud committed for the company's benefit, from data manipulation to pricing fraud, can engage the ECCTA offence. DefenceFile organises the evidence that fraud-prevention procedures were in place across trials, distribution, and the third parties acting for you.
Not sure if you are in scope? Most pharmaceuticals and life sciences that meet the large-organisation size test are in scope — check the size test or the scope Q&A.
The sample board pack opens in your browser — no email, no form. 90-day pilots are £950/month; the setup fee is waived if the first working session does not produce the agreed artifacts.
Why pharmaceuticals and life sciences tend to be in scope
Large pharma groups and contract manufacturers readily meet the size test on turnover and headcount once group and overseas entities are considered. Extensive use of CROs, distributors, and commercial agents makes associated-person mapping across the trial-to-market chain the central scoping task, and whether each third party qualifies is a legal judgement for qualified reviewers.
Scope is a legal assessment that turns on your group size and facts. See the UK-nexus and scope Q&A and reserve the conclusion for qualified reviewers.
Associated persons to map in pharmaceuticals
An associated person is wider than payroll. These are the relationships worth organising evidence around for this sector.
- Contract research organisations and clinical trial sites
- Wholesalers, distributors, and parallel-trade intermediaries
- Commercial agents and market-access consultants
- Medical science liaisons and key-opinion-leader engagements
- Contract manufacturers and supply-chain auditors
Fraud scenarios and the evidence to capture
Illustrative scenarios where a listed base fraud offence could be committed to benefit the organisation. They are prompts for human review, not findings.
Manipulation or fabrication of clinical-trial or safety data to secure approvals, funding, or market position for the company's product.
Evidence focus: Capture the data-integrity controls, monitoring records, and CRO oversight evidence applied across trial sites.
Pricing, rebate, or reimbursement fraud against the NHS or payers — including misreported list prices or improper rebate claims that benefit the company.
Evidence focus: Organise the verification and approval records over pricing submissions, rebate calculations, and payer reporting.
Improper inducements to prescribers or distributors structured to drive volume and revenue toward the company's products.
Evidence focus: Record the transfer-of-value, conflict, and engagement-approval evidence over prescriber and distributor relationships.
What the defence file should prioritise
- A register of CRO, distributor, and agent due-diligence and monitoring with the checks applied
- Attestations from third parties on data-integrity and anti-fraud expectations
- Records of pricing, rebate, and payer-reporting verification and sign-off
- Board oversight of trial-data, pricing, and inducement fraud risk across the group
Pharmaceuticals ECCTA fraud questions
- Are CROs and distributors associated persons for ECCTA?
- A CRO, distributor, or commercial agent may be an associated person where it performs services for or on behalf of the company. The classification depends on the facts; DefenceFile organises the third-party evidence so reviewers can assess each relationship.
- How do we evidence controls over clinical-trial data integrity?
- Maintain a register of monitoring, data-integrity, and CRO-oversight records linked to your fraud-prevention policies. The platform keeps these discoverable and review-ready without asserting the underlying data is sound.
- Does DefenceFile validate our pricing submissions?
- No. DefenceFile does not verify pricing or judge whether procedures are reasonable. It organises the evidence of the checks your regulatory, commercial, and advisory teams carry out.
Related sectors
- HealthcareHealthcare and care groups bill payers and use agency staff and referrers that create ECCTA fraud exposure. Organise a reviewable defence file.
- ManufacturingHow manufacturers organise ECCTA failure-to-prevent-fraud evidence across distributors, agents, and suppliers — scope, risks, and a defence file.
- LogisticsHow haulage firms organise ECCTA failure-to-prevent-fraud evidence across carriers, brokers, and customs agents — scope, risks, and a defence file.
Keep going
- Failure to prevent fraud: the offence explainedThe statutory offence, the size test, and what a defence file is for.
- Reasonable proceduresHow the six principles map to evidence you can organise and review.
- Failure to prevent fraud: straight answersDirect, sourced answers on scope, penalties, the deadline, and the defence.
- Pricing and pilotsHow a structured pilot review of your evidence works.
DefenceFile organises evidence for legal and compliance review. It does not provide legal advice, create privilege, certify scope, certify reasonable procedures, or guarantee that a statutory defence will succeed.